Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–10 of 10 results
Advanced filters: Author: Gaurav D. Gaiha Clear advanced filters

  • Understanding the heterogeneity of HIV infection, such as in persons with non-suppressible HIV-1 viremia despite adherence to antiretroviral treatment, is crucial to better tailor therapeutic interventions to abrogate HIV-1 persistence.

    • Abbas Mohammadi
    • Behzad Etemad
    • Jonathan Z. Li
    ResearchOpen Access
    Nature Medicine
    Volume: 29, P: 3212-3223

  • Cytotoxic lymphocytes (CTL) are important in the control of HIV and some HLA alleles are associated with protection or susceptibility to disease. Here the authors characterise an epitope where variants bind to HLA-B57 or HLA-B53 and they characterise the structural and functional TCR recognition differences.

    • Xiaolong Li
    • Nishant Kumar Singh
    • Jia-huai Wang
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-15

  • ESCAPE-seq (enhanced single-chain antigen presentation sequencing) is a massively parallel platform for screening of class I HLA–peptide combinations for antigen presentation. The authors assess more than 75,000 peptide–HLA combinations, revealing presented epitopes from oncogenic driver mutations and fusions across diverse HLA-A, HLA-B and HLA-C alleles.

    • Quanming Shi
    • Elana P. Simon
    • Howard Y. Chang
    ResearchOpen Access
    Nature Genetics
    Volume: 57, P: 2062-2073

  • mRNA technologies offer potential solutions for HIV-1 vaccine development by enabling rapid, safe and modular antigen design that can initiate rare antibody lineages required for broad protection. In this Review, we discuss preclinical and early clinical evidence, outline remaining challenges — particularly breadth and durability — and discuss delivery and manufacturing advances that may help translate these approaches into effective preventive and therapeutic strategies.

    • Chuang Liu
    • Alexey V. Yaremenko
    • Wei Tao
    Reviews
    Nature Reviews Bioengineering
    Volume: 4, P: 435-453

  • The US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institute of Health (NIH), convened a virtual workshop on August 8-9th, 2023 to explore potential synergies between HIV vaccine approaches that are designed to induce cellular or humoral immune responses. The goal of this workshop was to review data on leading vaccine candidates and to discuss the best strategies for combining these approaches to optimize immunity against HIV. Here, we summarize the findings reviewed at the workshop and discuss the knowledge gaps and priorities for future studies that will help accelerate the development of a preventive HIV vaccine.

    • Milton Maciel Jr
    • Rama R. Amara
    • M. Patricia D’Souza
    News & ViewsOpen Access
    npj Vaccines
    Volume: 9, P: 1-6

  • Recently, antibody-mediated control of HIV infection has received considerable attention. Here, the authors discuss the importance of CD8+ T cells in HIV infection and suggest that efforts to develop vaccines that target these cells in conjunction with B cells should be renewed.

    • David R. Collins
    • Gaurav D. Gaiha
    • Bruce D. Walker
    Reviews
    Nature Reviews Immunology
    Volume: 20, P: 471-482